RECRUITING

Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals

Conditions

Prediabetes / Type 2 Diabetes Whey Protein type II diabetes Protein turnover Dietary intake

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To examine the effects of twice daily whey protein consumption on blood glucose and insulin in pre-diabetic and diabetic individuals

Official Title

Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals

Quick Facts

Study Start:2025-01-15

Study Completion:2026-11-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06694155

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 70 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Males and females ages 50-70 years. 2. Capable of providing informed consent. 3. COVID-19 negative and/or asymptomatic. 4. Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 7-day study meal period on two occasions. 5. HbA1c: 5.7-6.4% or 6.5% to 7.5%	1. Subject who does not/will not eat dairy protein sources. 2. Subjects taking exogenous insulin injections or GLP /GIP injections or other appetite suppressants. 3. Unwilling to keep a detailed 7 day food journal on two occasions 4. Unwilling to wear a CGM for 7 days on two occasions and share the data with the research team. 5. Lactose intolerance. 6. Hemoglobin \<10g/dL at screening. 7. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment. 8. History of gastrointestinal bypass/reduction surgery. 9. Pregnant or lactating individuals. 10. History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease) 11. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy. 12. Currently using corticosteroid medications (cortisone, hydrocortisone, prednisone, etc.). 13. Unwilling to avoid using protein or amino-acid supplements during participation. 14. Unwilling to fast overnight. 15. Any medical condition or medication that the PI or clinical study staff finds contradictory to this study.

Inclusion Criteria

Exclusion Criteria

1. Males and females ages 50-70 years.
2. Capable of providing informed consent.
3. COVID-19 negative and/or asymptomatic.
4. Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 7-day study meal period on two occasions.
5. HbA1c: 5.7-6.4% or 6.5% to 7.5%

1. Subject who does not/will not eat dairy protein sources.
2. Subjects taking exogenous insulin injections or GLP /GIP injections or other appetite suppressants.
3. Unwilling to keep a detailed 7 day food journal on two occasions
4. Unwilling to wear a CGM for 7 days on two occasions and share the data with the research team.
5. Lactose intolerance.
6. Hemoglobin \<10g/dL at screening.
7. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment.
8. History of gastrointestinal bypass/reduction surgery.
9. Pregnant or lactating individuals.
10. History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease)
11. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy.
12. Currently using corticosteroid medications (cortisone, hydrocortisone, prednisone, etc.).
13. Unwilling to avoid using protein or amino-acid supplements during participation.
14. Unwilling to fast overnight.
15. Any medical condition or medication that the PI or clinical study staff finds contradictory to this study.

Contacts and Locations

Study Contact

Arny Ferrando, PhD

CONTACT

5015265711

aferrando@uams.edu

Study Locations (Sites)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72202

United States

Collaborators and Investigators

Sponsor: University of Arkansas

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-15

Study Completion Date2026-11-01

Study Record Updates

Study Start Date2025-01-15

Study Completion Date2026-11-01

Terms related to this study

Keywords Provided by Researchers

Whey Protein
type II diabetes
Protein turnover
Dietary intake

Additional Relevant MeSH Terms

Prediabetes / Type 2 Diabetes